Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)




Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)

VANCOUVER, British Columbia, March 16, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) is pleased to announce the commencement of its commercial phased rollout of the Marijuana Breath Test (“MBT”) system. This phase includes the delivery of MBT units to select commercial customers across multiple industries, followed by a planned scale-up in production.

The Marijuana Breath Test fills a critical gap and delivers new technology and methods that provide a complete, non-invasive solution for detecting recent cannabis use, specifically delta-9 THC (the primary psychoactive compound in cannabis) in breath, within approximately 4 hours of consumption at levels above 5 pg/L. This capability addresses a long-standing need among employers, law enforcement agencies, and safety-sensitive industries, which have historically relied on testing methods that detect primarily past cannabis use. As legalized recreational and medical marijuana use continues to expand across the United States and globally, accurate detection of recent use via breath is becoming essential for maintaining fairness, relevance, and informed decision-making. See product video link: https://cannabixtechnologies.com/products/cannabix-marijuana-breath-test/

Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.

In early March 2026, an independent peer-reviewed publication in the Journal of Analytical Toxicology (JAT) became publicly available confirming the ability of the MBT system to detect delta-9 THC.

Over recent months, Cannabix and its partners have completed many initiatives to enable the commercial rollout of the MBT system:

• Key enhancements to the Breath Collection Unit (BCU) and Breath Cartridges (Figures 1 and 2), along with the initial validation package prepared by Omega Laboratories (“Omega”).
• Integration of Cannabix Breath Cartridges into Omega’s operational workflows, including chain-of-custody processes and electronic reporting through its Laboratory Information Management System (LIMS).
• Established manufacturing procedures and partnerships, standard operating procedures, and QA/QC processes for MBT hardware.
• BCU successfully passing FCC electronic emissions testing.
• The MBT system will follow a recurring revenue model in which the handheld BCU serves as the required hardware for all deployments, while disposable Breath Cartridges generate ongoing revenue as they are used for every test performed.
• Pre-launch marketing initiatives conducted with Omega (Ohio) and AlcoPro (Knoxville, TN).
• Preparation of end-user training materials, logistics planning, and customer support resources.
• Release of peer-reviewed Journal of Analytical Toxicology publication, titled: “Simultaneous Analysis of Δ9-THC, Δ8-THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit.” (March 2026) link: https://doi.org/10.1093/jat/bkag016

The MBT platform consists of the Cannabix Breath Collection Unit (BCU), disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega Laboratories. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a world-class facility with extensive experience in novel drug detection technologies.

Why Recent Use Detection of Cannabis Is Important
Traditional cannabis testing methods such as urine, saliva, or hair analysis, primarily detect historical cannabis use. These methods can return positive results hours, days, or even weeks after consumption, making them ineffective for determining whether an individual may be using during the workday.

Figure 2. Cannabix Marijuana Breath Test hardware with Breath Collection Unit (BCU) taking a breath sample.

Scientific research shows that delta-9 THC is detectable in breath for a short window of approximately 2–4 hours, closely aligned with the period of peak impairment. Breath analysis therefore provides the most relevant and scientifically meaningful indication of recent use, which is the metric employers and safety-sensitive industries require.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. Visit www.cannabixtechnologies.com

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company’s plans for commercial rollout of the MBT system; anticipated customer adoption and market demand; expectations regarding manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company’s ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “proposed,” “target,” “will,” and similar expressions, or statements that events or conditions “may” or “will” occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the ability of the Company to successfully manufacture, deploy, and commercialize the MBT system or any future products; risks related to regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory partnerships and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks associated with future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0493eed8-0bf0-4516-954e-2eea2c1d51c5

https://www.globenewswire.com/NewsRoom/AttachmentNg/744a24c4-3365-4d61-9428-9da999cc669f

Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease




Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease

Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential to be superior to monoclonal antibodies and restore neuronal function while halting or reversing disease progression 

NOVATO, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Amlogenyx Inc., a biotechnology company focused on developing gene therapies for Alzheimer’s disease and other neurodegenerative diseases, today announced multiple positive results from a broad series of preclinical studies of AM805, an investigational AAV9 gene therapy for the treatment of Alzheimer’s disease. The results demonstrate that delivery of the carboxypeptidase called protective protein cathepsin A (PPCA), a potent lysosomal enzyme, was successful in reducing amyloid in the brain of both severe and moderate animal models of Alzheimer’s disease in both young and aged mice. The data will be presented in a poster session, taking place March 19-21, and in an ePoster at the AD/PD^TM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen, Denmark and online. 

Arjun Natesan, the head of early R&D at Amlogenyx, said: “Despite clear biology implicating amyloid in Alzheimer’s and other neurodegenerative diseases, treatments that can halt, or possibly even reverse, disease progression have eluded researchers to date. Amlogenyx was founded to pursue an entirely novel approach of reducing amyloid burden in the brain by delivering a potent lysosomal enzyme which would enable clearance of the intracellular burden as well as enable clearance of plaque outside of cells. We are extremely pleased to present preclinical data demonstrating that AM805 can achieve robust amyloid reduction in the CNS and reduce both intracellular and extracellular amyloid, even in advanced disease, underscoring its strong potential to prevent and treat this devastating and intractable disease.”

In the central nervous system, amyloid is a key driver of Alzheimer’s disease, disrupting cellular homeostasis by impairing synaptic function, activating microglia, and triggering chronic neuroinflammation. In the data presented at AD/PD 2026, researchers from Amlogenyx and St. Jude Children’s Research Hospital identified a specific lysosomal enzyme – PPCA – that degrades amyloid efficiently. To address this, researchers engineered AM805, an AAV9-PPCA vector, to deliver PPCA to the CNS and reduce amyloid burden.
        
Study results showed that all routes of dosing resulted in increased PPCA activity and reduced amyloid-positive brain area in a dose-dependent manner in mouse models of both severe and moderate Alzheimer’s disease. The magnitude of reduction achieved was comparable to, and in some cases exceeded, that reported for approved Alzheimer’s disease monoclonal antibodies. Aβ peptide levels (4G8 positive signal) were lowered in both intracellular and extracellular compartments. Importantly, PPCA produced these reductions across multiple routes of administration, demonstrating that regardless of how the enzyme reaches the brain, it is therapeutically effective. The data also show that the enzyme can be delivered safely to the brain in non-human primates and achieve levels of enzyme expression consistent with the therapeutic effect in the AD mouse models.

These data are being presented at the AD/PD Conference in Poster #3157, Shift #2, from March 19–21. The ePoster and associated audio presentation will also be available on the meeting platform.

AM805 is currently being tested in IND-enabling studies and the Company plans to pursue an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration for AM805 in 2027.

About Alzheimer’s Disease
Alzheimer’s disease is a progressive, degenerative brain disorder and the most common cause of dementia, gradually affecting memory, thinking, behavior, and the ability to carry out daily activities. It is characterized by changes in the brain that begin years before symptoms appear and worsen over time. A hallmark of the disease is the abnormal accumulation of amyloid in the brain, which is believed to play an important role in the development and progression of Alzheimer’s. Alzheimer’s affects millions of individuals and families worldwide, underscoring the urgent need for continued research, earlier detection, improved treatments, and comprehensive support for patients and caregivers.

About AM805
AM805 is a novel protease delivered via AAV9 gene therapy for the treatment of Alzheimer’s disease that functions to reduce amyloid, a biomarker that helps predict progression of Alzheimer’s disease. AM805 utilizes an AAV9 gene therapy vector to deliver protective protein cathepsin A (PPCA), a lysosomal carboxypeptidase that degrades amyloid, directly to the brain. AM805 has been shown to substantially reduce amyloid (Aβ42) in preclinical models of Alzheimer’s disease – beyond the capabilities of traditional monoclonal antibody treatments. This investigational one-time gene therapy for Alzheimer’s disease has the potential to significantly alter the course of the disease by preventing and reversing amyloid plaque build-up and promoting neuronal health.

About Amlogenyx
Amlogenyx is dedicated to the development of a novel gene therapy strategy to reduce amyloid accumulation in the brain in order to prevent and treat diseases such as Alzheimer’s disease. Treatment with monoclonal antibodies to reduce amyloid has been shown to potentially slow the disease but not stop or reverse it, underscoring the need for improved treatment options. The Company is developing AM805, a novel protease therapy shown to reduce amyloid (Aβ42) accumulation in preclinical models of Alzheimer’s disease. Amlogenyx is a subsidiary of Ultragenyx. For more information on Amlogenyx, please visit the company’s website at: https://www.amlogenyx.com/.

Amlogenyx Contacts 

Investors and Media:
info@amlogenyx.com

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting




Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting.

This premier annual gathering of neuro‑ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders.
As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential global scientific meeting in neuro‑ophthalmology, reinforcing its commitment to advancing scientific progress in this field.

NANOS 2026
March 20-24, Boston, MA, USA

“Improved Low-Contrast Visual Acuity and Reduction in Retinal Ganglion Cell Loss with Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial”.

• Presenter: Professor Martin S. Zinkernagel, M.D., Ph.D., Chair of the Department of Ophthalmology at the University Hospital of Bern, Switzerland
• Date/Time: Monday March 23, 8:48 AM EDT 

The presentation of the Phase 2 ACUITY trial results investigating Privosegtor in patients with optic neuritis (ON) will focus on the significant improvements in low contrast visual acuity and promising neuroprotective structural and biological effects observed in the study. Privosegtor, a peptoid small molecule with the ability to cross both the blood brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis, with broad potential applicability in other neuro-ophthalmic and neurological diseases. Following Breakthrough Therapy designation from the U.S. Food and Drug Administration for ON, Oculis is advancing the PIONEER registrational program for Privosegtor in optic neuropathies, with the PIONEER-1 trial in optic neuritis initiated in Q4 2025. 

Riad Sherif, M.D., Chief Executive Officer of Oculis, said “Our commitment to advancing the field of neuro‑ophthalmology has never been stronger. The ACUITY Phase 2 results with Privosegtor highlight meaningful progress toward delivering a much‑needed neuroprotective therapy to patients with optic neuritis and other optic neuropathies. The opportunity to present the groundbreaking data from this trial at NANOS, recognized as the most important global forum for neuro‑ophthalmic science, represents a significant milestone for Oculis and for patients. As a Platinum Sponsor for this year’s congress, we are honored to support and partner with the scientific community in shaping the future of neuroprotective therapies.”

Martin Zinkernagel, M.D., Ph.D., is Professor and Chair of the Department of Ophthalmology at the University Hospital of Bern, Switzerland, as well as director of the internationally renowned Bern Photographic Reading Center at the University of Bern. Professor Zinkernagel is highly recognized in the field with over 270 publications spanning his research interests in retinal imaging, ophthalmic data analysis using artificial intelligence, and the influence of the gut microbiome in retinal disease. He earned his M.D. at the University of Zurich and his PhD in ocular immunology and gene therapy from the University of Western Australia.

–END–

About Privosegtor

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic diseases. Positive results from the ACUITY Phase 2 trial demonstrated Privosegtor’s neuroprotective potential through anatomical preservation of the retina and improvements in visual function after an acute episode of optic neuritis. Consistent results were observed in animal models of neuroinflammation and neurodegeneration, where Privosegtor preserved retinal ganglion cell damage and was associated with improvements in mobility (clinical function disability). Privosegtor has received Breakthrough Therapy designation from the FDA and Orphan Drug designation from both the FDA and the EMA for ON and is now entering registrational trials for this indication, as well as a registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION), as part of Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program. In addition to its potential neuroprotective effect on the optic nerve, Privosegtor could also have wide applicability in treating other neuro-ophthalmic and neurological indications.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About Optic Neuritis

Optic Neuritis (ON) is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. annual incidence estimated to be >30,000 and often represents the first sign of multiple sclerosis^1,2. It mainly occurs in adults between the age of 20 and 40 years and is more frequent in women (2:1)³. ON is a type of neuropathy (nerve disease) that happens when acute inflammation of the optic nerve affects the signals traveling from the eyes through the brain, causing pain, vision loss and other symptoms. The cells that make up the optic nerve have a lipid protective coating called a myelin sheath, which is preferentially damaged in ON. Without myelin, the optic nerve cells can’t send signals properly and axons can be irreversibly lost. To date there is no specific therapy approved for acute optic neuritis and the unmet needs remain for therapies that can prevent vision loss after an acute episode by reducing nerve cell permanent damage or death.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in registrational trial, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; and Oculis’ future development plans, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

1. Martínez-Lapiscina EH, et al. (2014): Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain) 2008-2012. J Neurol. 2014 Apr; 261(4): 759-767.
2. Weidong Gu et al. (2023) Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Members of U.S. Armed Forces, Military Medicine, vol. 188, March/April 2023
3. Guier CP, Kaur K, Stokkermans TJ. Optic Neuritis. January 2025. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK557853

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting




Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

ZUG, Switzerland, 16 March, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting.

This premier annual gathering of neuro-ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders.

As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential global scientific meeting in neuro-ophthalmology, reinforcing its commitment to advancing scientific progress in this field.

NANOS 2026
March 20-24, Boston, MA, USA

“Improved Low-Contrast Visual Acuity and Reduction in Retinal Ganglion Cell Loss with Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial”.

• Presenter: Professor Martin S. Zinkernagel, M.D., Ph.D., Chair of the Department of Ophthalmology at the University Hospital of Bern, Switzerland
• Date/Time: Monday March 23, 8:48 AM EDT 

The presentation of the Phase 2 ACUITY trial results investigating Privosegtor in patients with optic neuritis (ON) will focus on the significant improvements in low contrast visual acuity and promising neuroprotective structural and biological effects observed in the study. Privosegtor, a peptoid small molecule with the ability to cross both the blood brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis, with broad potential applicability in other neuro-ophthalmic and neurological diseases. Following Breakthrough Therapy designation from the U.S. Food and Drug Administration for ON, Oculis is advancing the PIONEER registrational program for Privosegtor in optic neuropathies, with the PIONEER-1 trial in optic neuritis initiated in Q4 2025. 

Riad Sherif, M.D., Chief Executive Officer of Oculis, said “Our commitment to advancing the field of neuro-ophthalmology has never been stronger. The ACUITY Phase 2 results with Privosegtor highlight meaningful progress toward delivering a much-needed neuroprotective therapy to patients with optic neuritis and other optic neuropathies. The opportunity to present the groundbreaking data from this trial at NANOS, recognized as the most important global forum for neuro-ophthalmic science, represents a significant milestone for Oculis and for patients. As a Platinum Sponsor for this year’s congress, we are honored to support and partner with the scientific community in shaping the future of neuroprotective therapies.”

Martin Zinkernagel, M.D., Ph.D., is Professor and Chair of the Department of Ophthalmology at the University Hospital of Bern, Switzerland, as well as director of the internationally renowned Bern Photographic Reading Center at the University of Bern. Professor Zinkernagel is highly recognized in the field with over 270 publications spanning his research interests in retinal imaging, ophthalmic data analysis using artificial intelligence, and the influence of the gut microbiome in retinal disease. He earned his M.D. at the University of Zurich and his PhD in ocular immunology and gene therapy from the University of Western Australia.

–END–

About Privosegtor

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic diseases. Positive results from the ACUITY Phase 2 trial demonstrated Privosegtor’s neuroprotective potential through anatomical preservation of the retina and improvements in visual function after an acute episode of optic neuritis. Consistent results were observed in animal models of neuroinflammation and neurodegeneration, where Privosegtor preserved retinal ganglion cell damage and was associated with improvements in mobility (clinical function disability). Privosegtor has received Breakthrough Therapy designation from the FDA and Orphan Drug designation from both the FDA and the EMA for ON and is now entering registrational trials for this indication, as well as a registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION), as part of Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program. In addition to its potential neuroprotective effect on the optic nerve, Privosegtor could also have wide applicability in treating other neuro-ophthalmic and neurological indications.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About Optic Neuritis

Optic Neuritis (ON) is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. annual incidence estimated to be >30,000 and often represents the first sign of multiple sclerosis^1,2. It mainly occurs in adults between the age of 20 and 40 years and is more frequent in women (2:1)³. ON is a type of neuropathy (nerve disease) that happens when acute inflammation of the optic nerve affects the signals traveling from the eyes through the brain, causing pain, vision loss and other symptoms. The cells that make up the optic nerve have a lipid protective coating called a myelin sheath, which is preferentially damaged in ON. Without myelin, the optic nerve cells can’t send signals properly and axons can be irreversibly lost. To date there is no specific therapy approved for acute optic neuritis and the unmet needs remain for therapies that can prevent vision loss after an acute episode by reducing nerve cell permanent damage or death.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in registrational trial, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; and Oculis’ future development plans, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

1. Martínez-Lapiscina EH, et al. (2014): Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain) 2008-2012. J Neurol. 2014 Apr; 261(4): 759-767.
2. Weidong Gu et al. (2023) Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Members of U.S. Armed Forces, Military Medicine, vol. 188, March/April 2023
3. Guier CP, Kaur K, Stokkermans TJ. Optic Neuritis. January 2025. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK557853 

Dvorak Botanicals Launches Low-Dose Hemp-Derived THC Gummies Focused on Mindful Consumption




Dvorak Botanicals Launches Low-Dose Hemp-Derived THC Gummies Focused on Mindful Consumption

Atlanta, GA, March 16, 2026 (GLOBE NEWSWIRE) — Dvorak Botanicals, a new premium hemp-derived THC brand founded by Atlanta-based entrepreneur Dane Dvorak, has launched with a focus on controlled-dose hemp products that support more intentional and balanced ways for adults to relax.

Dvorak Botanicals’ 2.5mg hemp-derived THC gummies in Yuzu and Peach, designed for a controlled, low-dose experience.

The company’s initial product line features low-dose hemp-derived Delta-9 THC gummies. Each gummy contains 2.5 mg of THC, allowing users to control their experience through gradual dosing. The gummies are packed in 20-count containers and formulated with premium flavor profiles such as yuzu and peach, reflecting the company’s emphasis on elevated ingredients and approachable formulations.

The launch comes as consumer interest in mindful consumption continues to grow. Many adults are exploring alternatives to traditional alcohol-centered social experiences or high-potency cannabis products. By focusing on controlled, low-dose formats, Dvorak Botanicals aims to offer a more approachable option for adults looking to unwind, connect socially, and incorporate cannabis into their routines.

“Many cannabis products are designed for intensity, but not necessarily for balance,” said Dane Dvorak, founder of Dvorak Botanicals. “We wanted to create something that allows adults to ease into the experience, control their dosage, and enjoy THC thoughtfully.”

All Dvorak Botanicals products undergo third-party laboratory testing for potency and purity to help ensure product consistency and transparency for consumers. The gummies are formulated using hemp-derived Delta-9 THC in accordance with federal hemp regulations.

In addition to direct-to-consumer sales through the company’s website, Dvorak Botanicals products are currently carried by select independent boutiques across Georgia, including Soberish, Ghost Apothecary, and The Zero Co. The company partners with retailers that align with its design-focused and wellness-oriented brand philosophy and is actively expanding its retail presence through the region. Dvorak Botanicals plans to grow into a broader wellness platform built around intentional relaxation and thoughtful dosing practices.

“Our focus starts with cannabinoids,” Dvorak added, “but the larger goal is to build a brand people trust for premium products and more mindful ways to relax.”

To learn more, please visit https://dvorakbotanicals.com.

About Dvorak Botanicals
Dvorak Botanicals is a modern hemp-derived THC brand created for adults exploring more balanced ways to relax and socialize. The company combines thoughtful dosing with elevated product design to create approachable cannabinoid experiences. Dvorak Botanicals is focused on building a lifestyle brand that supports mindful consumption and contemporary wellness habits.

Media Contact
Company Name: Dvorak Botanicals
Contact Person: Dane Dvorak
Contact Number: 404-436-2280
Email: support@dvorakbotanicals.com
Country: United States
Website: https://dvorakbotanicals.com
Social Media Handles: @Dvorak.botanicals

CONTACT: Media Contact
Company Name: Dvorak Botanicals
Contact Person: Dane Dvorak
Contact Number: 404-436-2280
Email: support@dvorakbotanicals.com
Country: United States
Website: https://dvorakbotanicals.com
Social Media Handles: @Dvorak.botanicals

GN Store Nord A/S enters into agreement to sell its Hearing business to Amplifon S.p.A. for DKK 17.0 billion




GN Store Nord A/S enters into agreement to sell its Hearing business to Amplifon S.p.A. for DKK 17.0 billion

Today, GN Store Nord A/S (“GN”) has entered into a definitive agreement for the sale of GN’s Hearing business to Amplifon S.p.A. (“Amplifon”), a leading global hearing care retailer. The transaction values the Hearing business at DKK 17.0 billion¹ on a cash-free and debt-free basis and will be settled with DKK 12.6 billion² in cash and 56 million shares in Amplifon. The transaction is subject to customary regulatory approvals and completion of the Hearing business separation from GN and is expected to complete by the end of 2026.

Amplifon and GN will together create a global integrated leader in audiology combining hearing technology leadership with high-quality, innovative hearing care to offer comprehensive solutions to both audiology professionals and patients. The combination will create the industry leader in hearing care solutions and services worldwide with benefits to audiologists, consumers, and investors.

Following the transaction, GN will fully focus to drive success in the large and attractive audio and video peripherals markets. GN is well positioned with leading brands, premium product differentiation, and technology leadership in sound processing and low-power edge AI. Financially, GN will drive margin expansion supported by the product differentiation and its scalable and agile operations setup, while the asset-light business model will support healthy cash flows.

As the proceeds from the transaction is larger than GN’s net interest-bearing debt, GN expects to use the proceeds to 1) significantly reduce debt, 2) invest in the ongoing business to support sustainable and profitable growth as well as 3) returning capital to shareholders, subject to applicable law and in line with the dividend policy.

GN Store Nord Chair Jukka Pekka Pertola said:
We are excited to transform GN into a pure technology company. We have unique positions and capabilities making us well positioned to further grow in the large audio and video peripherals market in a focused way. While we will miss all of our great employees in Hearing, we are proud that we, together with Amplifon, will create an industry leading player in global audiology. We are convinced that the transaction and steps ahead will be beneficial to our customers, employees and investors.
  
GN Store Nord CEO Peter Karlströmer said:
We are today acting on an opportunity to create a global leader in audiology together with Amplifon. The new company has every chance to develop into an industry leader driving further innovation and success in hearing care. For GN, this also creates an opportunity to further strengthen our position in the large and attractive audio and video peripherals markets. We have unique brands, talents, and capabilities and a rich set of opportunities. We have in the last few years strengthened GN significantly financially and operationally. As we open up this new chapter, we are focused on driving success as an innovative technology company with global reach and scale. This is very exciting for GN’s customers, employees, and investors.

Amplifon CEO Enrico Vita said: “Today marks a turning point for Amplifon. We are announcing the most transformative acquisition in our 75-year-long history, that will fundamentally change the future of the hearing care industry worldwide and create significant and long-term value for all our stakeholders. With combined revenues of approximately €3.3 billion, a presence in more than 100 countries, a cutting-edge R&D platform, leading manufacturing capabilities, and an unparalleled commercial network, we will be forming a truly global vertically integrated leader in audiology. Importantly, Amplifon will continue to preserve and enhance Hearing’s unique identity, heritage, and strengths, recognizing its brand value, culture, and distinct capabilities as key contributors to the future success of the combined organization. We look forward to working closely with the exceptional team at Hearing to improve hearing health for millions of people globally”

Background
Over the past years, GN has significantly strengthened its strategic focus and execution capabilities across the group, supported by substantial investments in innovation, technology, and its supply chain. These efforts have created a solid foundation for sustainable and profitable growth. During this period, the Board and Executive Management received several unsolicited expressions of interest, including from Amplifon, and subsequently engaged in exploratory discussions. One of these led to Amplifon making a financially and strategically compelling proposal with a high degree of deal certainty. After extensive deliberation and a thorough evaluation process, the Board and Executive Management unanimously decided to pursue and accept the proposal from Amplifon.

Transaction Highlights

• Consideration: DKK 17.0 billion³ on a cash-free and debt-free basis, comprised of DKK 12.6⁴ billion in cash (subject to customary true up closing mechanism adjustments) and 56 million shares in Amplifon, allowing GN to retain upside to the strong strategic value proposition of the transaction. Once the transaction closes, GN will hold approximately 16%⁵ of the current outstanding share capital in Amplifon, subject to customary lock-up
• Hearing Perimeter: Includes the entire Hearing business comprising of c. 5,500 employees globally, the ReSound, Beltone and other hearing brands, all hearing product IP, R&D, manufacturing and operations (including relevant sites used by the Hearing business), and Beltone network partnerships. The transaction does not include the current financial investment in Nations Benefits LLC. In 2025, the Hearing business generated revenue of DKK 7,214 million and reported pro-forma EBITDA of DKK 1,185 million⁶.
• Shareholders’ agreement: At closing, GN and Ampliter S.r.I, Amplifon’s controlling shareholder, are expected to enter into a shareholders’ agreement providing for GN’s right to propose a representative for appointment to Amplifon’s Board of Directors, together with customary transfer restrictions and lock-up undertakings in respect of the Amplifon shares received by GN as consideration. Additionally, Ampliter S.r.l., and core shareholder, Tamburi Investment Partners S.P.A., confirmed their financial support to the Transaction, including investment in a future equity raise conducted by Amplifon.
• Carve-out: Prior to closing of the transaction, the Hearing business will be separated from GN through a carve-out, including a statutory demerger of the Hearing business in accordance with the Danish Companies Act. The de-merger is expected to take place as a taxable transaction.
• Transitional Arrangements: Certain shared services and support functions by GN will continue to be provided on a temporary basis following the closing of the transaction via customary transitional services agreements between the parties.
• Fairness Opinions: J.P. Morgan Securities plc has provided to the Board of Directors of GN an opinion as of 16 March 2026 based on the factors, assumption and procedures specified therein, which confirms that the transaction value is fair from a financial point of view (the “Fairness Opinion”). J.P. Morgan provided its Fairness Opinion solely for the benefit and information of the Board of Directors of GN in its evaluation of the transaction, and the Fairness Opinion may not be relied upon by any third party or used for any other purpose. Additionally, Nordea Corporate Finance, part of Nordea Danmark, Filial af Nordea Bank Abp, Finland (“Nordea”), has as Independent Financial Advisor, provided to the Board of Directors of GN an opinion as of 16 March 2026 based on the factors, assumptions and procedures specified therein, which confirms that the transaction value is fair for GN from a financial point of view (the “Independent Fairness Opinion”). Nordea provided its Independent Fairness Opinion solely for the benefit and information of the Board of Directors of GN Store Nord A/S in its evaluation of the transaction, and the Independent Fairness Opinion may not be relied upon by any third party or used for any other purpose.
• Closing conditions: The transaction is subject to customary conditions, including merger control and other regulatory approvals from relevant authorities and completion of the Hearing business separation from GN.
• Anticipated Closing Date: The transaction is expected to close by the end of 2026. GN remains committed to serving the customers of the Hearing business and will continue delivering high-quality, innovative products.

Financial implications and guidance
As a direct consequence of the transaction, Hearing will be classified as discontinued operations, and associated assets and liabilities as held-for-sale.

GN’s financial guidance for 2026 now excludes discontinued operations and therefore only reflects Enterprise and Gaming. Consequently, the organic revenue guidance is now expected to be 2-8%, based on unchanged divisional assumptions of 0-6% organic revenue growth in Enterprise, and 7-13% organic revenue growth in Gaming.

To drive the necessary changes of this significant transaction, GN will incur one-off costs, including but not limited to transaction and carve-out costs, which will impact group EBITA in 2026. Following the establishment of a standalone operating system structure, the company is expected to re-introduce a profitability guidance.

The current long-term financial targets are suspended; however, the company’s ambition to drive strong profitable growth remains unchanged. GN is in a strong position to deliver healthy growth, strong profitability and an attractive cash conversion.

Capital Markets Day
GN intends to hold a Capital Markets Day post-closing of the transaction. The Capital Markets Day will cover among other subjects the future strategy, long-term financial targets, capital allocation policy, including further clarifications on distributing excess capital to shareholders.

Press Conference
GN will host a press conference at 09:30 CET on 16 March 2026.
Contact Group Media Manager Helge Coroli Frandsen at hcfrandsen@gn.com to sign up.

Investor and analyst conference call
GN will hold will host a teleconference at 12:00 CET on 16 March 2026. Please visit www.gn.com/investor to access the teleconference. Presentation material will be available on the website prior to the start of the teleconference.

Advisors
J.P. Morgan Securities plc is acting as exclusive financial advisor, and Gorrissen Federspiel Advokatpartnerselskab and Gianni & Origoni are acting as legal advisors, and PricewaterhouseCoopers has provided due diligence services to GN.

This announcement contains inside information within the meaning of Article 7 of Regulation (EU) No 596/2014 (the Market Abuse Regulation).

For further information, please contact:

Investor Relations
Rune Sandager +45 45 75 92 57

Media Relations
Steen Frentz Laursen +45 20 65 34 20

About GN  
GN brings people closer through our leading intelligent hearing, audio, video, and gaming solutions. Inspired by people and driven by innovation, we deliver technologies that enhance the senses of hearing and sight. We help people with hearing loss overcome real-life challenges, improve communication and collaboration for businesses, and provide great experiences for audio and gaming enthusiasts. GN was founded more than 150 years ago with a vision to connect the world. Today, inspired by our strong heritage, GN touches more lives than ever with our unique expertise and the broadest portfolio of products and services in our history – bringing people closer to what is important to them.

We market our solutions with the brands Jabra, ReSound, SteelSeries, Beltone, Interton, BlueParrott, Danavox, and FalCom in 100 countries. Founded in 1869, GN Group employs more than 7,500 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com – and connect with us on LinkedIn, Facebook and Twitter

About Amplifon
Amplifon, global leader in the hearing care retail market, empowers people to rediscover all the emotions of sound. Amplifon’s around 20,600 people worldwide strive every day to understand the unique needs of every customer, delivering exclusive, innovative and highly personalized products and services, to ensure everyone the very best solution and outstanding experience. The Group, with annual revenues of around 2.4 billion euros, operates through a network of around 10,000 locations in 25 Countries and 5 continents. More information about the Group is available at: https://corporate.amplifon.com.

The forward-looking statements in this announcement reflect the management’s current expectations of certain future events and financial results. Statements regarding the future are, naturally, subject to risks and uncertainties, which may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events, which may prove incorrect. Changes to such expectations and assumptions will not be disclosed on an ongoing basis, unless required pursuant to general disclosure obligations to which GN is subject.

Factors that may cause actual results to deviate materially from expectations include – but are not limited to – general economic developments and developments in the financial markets as well as foreign exchange rates, risks related to the above mentioned transaction, technological developments, changes and amendments to legislation and regulations governing GN markets, changes in the demand for GN products, competition, fluctuations in sub-contractor supplies, and developments in ongoing litigation (including but not limited to class action and patent infringement litigation in the United States).
For more information, please see the “Management’s report” and “Risk management” sections in the Annual Report. This announcement should not be considered an offer to sell or buy securities in.

^{1 Share component value based on €10.52 per Amplifon share as of 13 March 2026}

^{2 Cash component of EUR 1,690m converted to DKK at DKK/EUR 0.134}

^{3 Share component value based on €10.52 per Amplifon share as of 13 March 2026}

^{4 Cash component of EUR 1,690m converted to DKK at DKK/EUR 0.134}

^{5 Assumes Amplifon completes up to EUR 0.75bn equity raise as per Amplifon’s communication to the market. Should Amplifon not complete any equity raise, GN’s shareholding at closing would amount to 19.8%}

^{6 EBITDA includes group cost allocations and certain carve-out costs that the buyer will not take over, as well as other transaction adjustments of around DKK 230 million in total}